Becton Dickinson & Co

BD (Becton, Dickinson and Company) announced a $24 million investment from the U.S. Department of Defense and HHS to scale up U.S. manufacturing of the BD Veritor SARS-CoV-2 test, increasing production capacity by 50% to over 12 million test kits per month by February 2021.

Becton, Dickinson and Company (BD) acquired Straub Medical, a manufacturer of medical devices for treating arterial and venous diseases. The acquisition was completed on April 20, 2020.

Becton, Dickinson and Co. (BD) plans a two-phase expansion of its Mebane, North Carolina plant, investing $48 million by 2020 and $128 million by 2023, creating 116 jobs. The Alamance County Board of Commissioners approved $2.6 million in incentives.

Becton, Dickinson and Co. announced a $200 million investment across its Nebraska portfolio of sites in Columbus, Holdrege, and Broken Bow, supporting the creation of 300 new jobs. The investment was announced in October 2018.

Merit Medical Systems entered into an Asset Purchase Agreement to acquire a tunneled home drainage catheter product line from C.R. Bard and a soft tissue core needle biopsy product line from BD for $100 million, contingent on the BD-Bard merger closing.

BD (Becton, Dickinson and Company) broke ground on a $60 million expansion of its Columbus-East facility in Nebraska, adding 69,000 sq. ft. to become a flagship plastic injection molding plant.

Becton, Dickinson and Co. is investing $60 million in Nebraska to begin bringing plastics production in house.

Becton Dickinson & Co plans to invest approximately €110 million to expand its syringe manufacturing plant in Tatabánya, Hungary, adding production lines for prefilled syringes and plastic security devices. The expansion will create 219 jobs and is expected to begin construction between July and September 2017, with startup in 2020.